Spruce Biosciences Files 8-K
Ticker: SPRB · Form: 8-K · Filed: Oct 8, 2025 · CIK: 1683553
| Field | Detail |
|---|---|
| Company | Spruce Biosciences, Inc. (SPRB) |
| Form Type | 8-K |
| Filed Date | Oct 8, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $68.00, $67, $0.01, $50.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-securities, corporate-action
Related Tickers: SPRU
TL;DR
SPRU filed an 8-K on Oct 7th covering material agreements and equity sales.
AI Summary
On October 7, 2025, Spruce Biosciences, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing was made on October 8, 2025.
Why It Matters
This 8-K filing indicates significant corporate actions and potential equity transactions by Spruce Biosciences, Inc.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can impact stock price, including definitive agreements and equity sales.
Key Players & Entities
- Spruce Biosciences, Inc. (company) — Registrant
- October 7, 2025 (date) — Earliest event reported
- October 8, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 001-39594 (identifier) — Commission File Number
- 81-2154263 (identifier) — IRS Employer Identification No.
- 611 Gateway Boulevard, Suite 740 (address) — Principal executive offices
- South San Francisco, California (location) — Principal executive offices location
- 94080 (zip_code) — Principal executive offices zip code
- (415) 655-4168 (phone_number) — Registrant's telephone number
FAQ
What specific material definitive agreement did Spruce Biosciences, Inc. enter into?
The filing indicates the entry into a material definitive agreement but does not specify its nature in the provided text.
What was the date of the earliest event reported in this 8-K filing?
The earliest event reported was on October 7, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed on October 8, 2025.
What is Spruce Biosciences, Inc.'s state of incorporation and principal executive office location?
Spruce Biosciences, Inc. is incorporated in Delaware and its principal executive offices are located at 611 Gateway Boulevard, Suite 740, South San Francisco, California, 94080.
Does this filing mention any unregistered sales of equity securities?
Yes, the filing lists 'Unregistered Sales of Equity Securities' as an item of information.
Filing Stats: 1,593 words · 6 min read · ~5 pages · Grade level 12.6 · Accepted 2025-10-08 16:07:36
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share SPRB Nasdaq Capital Marke
- $68.00 — hase price per share of Common Stock is $68.00 per share (the "Purchase Price") and th
- $67 — se price for the Pre-Funded Warrants is $67.99, which equals the Purchase Price min
- $0.01 — ich equals the Purchase Price minus the $0.01 exercise price per Pre-Funded Warrant.
- $50.0 million — losing are expected to be approximately $50.0 million. The Pre-Funded Warrants have a per s
Filing Documents
- d36248d8k.htm (8-K) — 36KB
- d36248dex41.htm (EX-4.1) — 97KB
- d36248dex101.htm (EX-10.1) — 195KB
- 0001193125-25-234516.txt ( ) — 532KB
- sprb-20251007.xsd (EX-101.SCH) — 3KB
- sprb-20251007_lab.xml (EX-101.LAB) — 18KB
- sprb-20251007_pre.xml (EX-101.PRE) — 11KB
- d36248d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. These forward-looking statements include statements about the offering, such as the expected gross proceeds and anticipated closing date, and the timing of BLA submission and potential commercial launch. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the uncertainties related to market conditions and the completion of the offering on the anticipated terms or at all. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company's business are described in additional detail in the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025 and in the Company's other periodic and Current Reports filed with the SEC. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 4.1 Form of Pre-Funded Warrant to Purchase Common Stock. 10.1 Form of Securities Purchase Agreement, dated October 7, 2025, by and among Spruce Biosciences, Inc. and the Purchasers. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SPRUCE BIOSCIENCES, INC. Date: October 8, 2025 By: /s/ Samir Gharib Samir Gharib President and Chief Financial Officer